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Clinical Question
Is monitoring antiepileptic drug levels necessary?
Evidence-Based Answer
Routine monitoring of antiepileptic drug levels does not alter seizure or side effect rates. (Strength of
Recommendation [SOR]: B, based on a single randomized controlled trial [RCT] with less than 80 percent
follow-up). Antiepileptic drug level monitoring may be clinically useful in special populations, including
patients with suspected drug toxicity or noncompliance, pregnant patients, and patients with renal failure.
Monitoring dosage increases of drugs with nonlinear kinetics, such as phenytoin (Dilantin), may be useful.
(SOR: C, based on expert opinion). Therapeutic drug level monitoring of newer antiepileptic drugs has not
been shown to be clinically useful. (SOR: C, based on expert opinion).
Evidence Summary
Antiepileptic drug level monitoring has been routinely used since the advent of reliable assays of
phenytoin levels in the 1960s.1,2 At times, drug level monitoring is unnecessary and possibly harmful (e.g.,
indiscriminate antiepileptic drug level monitoring in a stable patient may create the potentially dangerous
situation of treating the level and not the patient).3 A study of antiepileptic drug level determinations at a
tertiary care center revealed that only 27 percent were appropriately indicated, and of those, one half were
sampled incorrectly.4
One RCT assessed the impact of antiepileptic drug level monitoring in patients with new-onset epilepsy.5
The study enrolled 180 patients with partial or idiopathic generalized epilepsy treated with carbamazepine
(Tegretol), valproate (Depakote), phenytoin, phenobarbital, or primidone (Mysoline). Using an open-label,
parallel group design, patients were randomized to two groups (a monitored group or a control group). In
the monitored group, drug dosage was adjusted to achieve a therapeutic level. In the control group, drug
dosage was adjusted on clinical grounds. Sixty-four percent of the patients completed the two-year study.
There was no significant difference between the monitored and control groups in the proportion of patients
who achieved a 12-month seizure-free remission (60 versus 61 percent, respectively; hazard ratio (HR) =
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0.96; 95% confidence interval, 0.50 to 1.63). The incidence of side effects was similar in the monitored
and control groups (48 versus 47 percent, respectively). A recent Cochrane review singles out this study
as the only one meeting its inclusion criteria, and concurs with its conclusions.6
As for the newer antiepileptic drugs, including gabapentin (Neurontin), lamotrigine (Lamictal),
oxcarbazepine (Trileptal), and topiramate (Topamax), there are no well-established therapeutic or toxic
drug levels.7 Thus, routine monitoring of levels of these drugs is generally not clinically useful. There are
several clinical situations in which antiepileptic drug level monitoring may be useful. These are
summarized in Table 1.1,8,9
Table 1. Clinical Situations in Which Antiepileptic Drug Level
Monitoring May Be Useful
Clinical situation Rationale
Strength of
recommendation References
Suspected
noncompliance
Determine probable cause of
seizures.
C 1, 8
Suspected drug toxicity Decrease drug dosage to achieve
nontoxic level.
C 1, 8
Increase phenytoin
(Dilantin) dosage
Nonlinear kinetics may result in
toxic level.
C 1, 9
Renal failure Decreased drug protein binding
may render "therapeutic" level
toxic.
C 8, 9
Pregnancy Decreased drug protein binding
may render "therapeutic" level
toxic.
C 8, 9
A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-
oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or
case series.
Information from references 1, 8, and 9.
Recommendations from Others
The Commission on Antiepileptic Drugs of the International League Against Epilepsy does not support
indiscriminate use of antiepileptic drug level determinations.3 It also cautions that using drug levels to
adjust dosage so that the numbers fall within the therapeutic range is a waste of time and money, and
could possibly be dangerous if drug therapy is effective and well tolerated. It recommends tailored
determinations if patients show signs of toxicity, if noncompliance is suspected, or if patients have
persistent seizures despite large dosages of drug. Also, monitoring drug level is reasonable when drugs
with zero order (nonlinear) kinetics (e.g., phenytoin) are not effective and the dosage is increased, or in
patients with an abnormal ratio of total to free drug levels (e.g., pregnant women).
The National Collaborating Centre for Primary Care states that regular drug level monitoring in adults is
not routinely recommended and should only be done if clinically indicated.10
Clinical Commentary
There are a few important caveats to this review that reflect the complexity of clinical practice and that
concern several issues not covered in these trials. First, the data presented here indicate active clinical
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assessment and surveillance for antiepileptic side effects. Physicians treating patients with seizure
disorders should be familiar with common agent-specific side effects, including gastrointestinal side
effects, vertigo, and ataxia with carbamazepine; nystagmus, ataxia, mental status changes with phenytoin;
and tremor, ataxia, lethargy, facial edema, anorexia, weight gain, and platelet dysfunction with valproate.
Physicians should also be aware of rare but serious side effects, such as blood dyscrasias, Stevens-
Johnson syndrome, respiratory depression, hepatic failure, and pancreatitis. Second, many of these drugs,
especially phenytoin, have multiple drug interactions that may cause an effect of "increase in dosage." In
these cases, it seems appropriate to check levels when starting therapy, especially with long-term
medications. Third, drug level monitoring is not the only monitoring required with these drugs. For
example, carbamazepine and phenytoin require a complete blood count at initiation and periodic hepatic
and renal function monitoring; and valproate requires periodic monitoring of liver function tests, especially
in the first six months. Fourth, in my teaching practice we see many patients with epilepsy and
developmental delays who are nonverbal or who may exhibit symptoms similar to antiepileptic side
effects at baseline (e.g., ataxia, nystagmus, dysarthria, tremor). Accordingly, assessing these patients for
side effects is challenging, and I would include them in the list of special populations that require regular
monitoring mentioned in this review. Finally, knowing the proper timing of sample collection is essential
to avoiding errors. Carbamazepine, valproate, and oral phenytoin should be tested after steady state has
been reached, just before the next dose is given, and at a consistent time of day.
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